CVS Health (CVS) Q3 2026 earnings review
CVS Health raises its profit outlook, while pharmacy margins tighten
CVS Health, the owner of CVS pharmacies, the Aetna health insurer and the Caremark pharmacy benefit manager, is riding an insurance rebound while drug benefit margins tighten. Revenue rose 5% and profit per share excluding one-offs jumped 31%, led by a near-tripling of operating profit in health insurance. Chief executive David Joyner raised the full-year profit outlook for a third straight quarter and lifted the operating cash flow target by $4 billion.
| Revenue | $108.4B +5.4% from a year ago |
|---|---|
| Profit per share, excluding one-offs | $2.09 +31% from a year ago |
| Insurance medical benefit ratio | 91.3% down 1.5 percentage points from a year ago |
| Full-year profit per share outlook | Raised to ≥$8.20 prior range: $7.90–8.10 |
⚖️ Verdict: 🟢 Bullish
The story got better because nine-month insurance profit already topped the company's prior full-year target, and retail pharmacies grew profit 11% even after lapping last year's Rite Aid prescription purchases. Furthermore, over 69% of Medicare Advantage members are in 2027 plans rated 4 stars or higher, securing government bonus payments. One caution: the company warned of elevated medical cost trends, and pharmacy benefit profit barely grew as client price concessions squeezed margins.
The question now is whether ongoing insurance margin gains can outrun 2027 pharmacy benefit headwinds and sticky hospital utilization. Either the fourth-quarter outlook floor of $0.96 per share by our math is another conservative buffer, or slowing reserve releases will expose real cost pressure. Management's 2027 commentary on the call and fourth-quarter medical costs will decide it.
🐂 Bull Case
Insurance Margin Recovery Tripled Segment Profit
CVS Health's biggest turnaround bet is Health Care Benefits, its Aetna health insurance arm. The company said higher profit this quarter came from "continued execution of its margin recovery plan" after exiting unprofitable individual insurance exchanges and repricing government plans. Segment operating profit, excluding one-offs, nearly tripled from a year ago as health care costs fell by 1.4 percentage points of segment revenue, by our math.
- Insurance operating profit, excluding one-offs: $912 million, up 190% from $314 million a year ago
- Medical benefit ratio (share of premiums spent on medical care): 91.3%, down 1.5 percentage points from 92.8% a year ago
- Government plan premiums: $28.1 billion, up 8.2% from a year ago
- 2027 Medicare Advantage quality ratings: over 69% of members in plans rated 4 stars or higher, ranking "second among large, publicly traded Medicare Advantage organizations in the Star Ratings program"
This matters because nine-month insurance profit of $6.38 billion already sits $1.18 billion above the middle of the full-year segment outlook management set last quarter. Even with a normal seasonal loss in the fourth quarter, the insurance recovery is running ahead of schedule, and strong Medicare star ratings protect government bonus payments for 2027.
What to watch: the fourth-quarter medical benefit ratio when full-year results arrive in February. A reading that keeps full-year medical costs below 89.5% of premiums would confirm that better plan pricing is outrunning hospital billing trends.
Third Straight Outlook Raise Lifts Cash Target
Since late 2024, management has tried to rebuild trust by setting conservative targets and beating them every quarter. Chief executive David Joyner said "each of our businesses delivered another quarter of strong results." CVS Health raised its full-year profit and cash outlook for a third consecutive quarter, lifting its operating cash flow floor by $4.0 billion to at least $15.5 billion.
The company generated $15.3 billion of operating cash flow in the first nine months, more than double the $7.2 billion it produced a year ago, helped by $3.6 billion from working capital timing. Because nine-month profit per share excluding one-offs already reached $7.24, the new full-year floor of at least $8.20 leaves only $0.96 for the fourth quarter by our math, down 12% from a year ago.
What to watch: the initial 2027 profit per share outlook on the fourth-quarter report. A floor at or above the $8.44 target discussed last quarter would show the company can grow earnings despite upcoming pharmacy benefit headwinds.
Retail Pharmacies Grew Profit Despite Lower Sales
Pharmacy & Consumer Wellness runs CVS Health's 9,000 retail drugstores. A standing concern was that drugstore growth would stall once the company lapped last year's purchase of prescription files from bankrupt rival Rite Aid. Same-store sales did dip 0.6% and total segment revenue fell 2.0% to $35.5 billion on drug price cuts and generic introductions, but segment operating profit excluding one-offs still rose 10.6% to $1.64 billion.
Profit grew while revenue shrank because cheaper generic drugs lowered the cost of products sold by 1.0 percentage point of segment revenue, lifting retail gross margin from 18.1% to 19.2%. Same-store prescription volume also rose 3.9% against an 8.9% jump a year ago, showing that underlying pharmacy demand held up past the Rite Aid anniversary.
What to watch: retail pharmacy same-store prescription volume in the fourth quarter. Growth staying near 4% would prove the drugstore chain can expand profits without relying on acquired Rite Aid customers.
🐻 Bear Case
High Medical Costs Pressure Late-Year Insurance Margins
While the Aetna turnaround is ahead of last year, patients are still using heavy amounts of medical care. CVS Health raised its outlook "while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds." In the third quarter, the medical benefit ratio climbed to 91.3%, up 3.9 percentage points from 87.4% in the second quarter.
Furthermore, earlier quarters received a big boost when reserves set aside for prior years' medical claims came in lower than feared. That favorable reserve development totaled $1.2 billion in the first six months, but added only $100 million in the third quarter by our math (reaching $1.3 billion for the nine months). Without big reserve releases, fourth-quarter insurance margins face the full weight of hospital and doctor billing trends.
What to watch: full-year favorable reserve development and fourth-quarter medical costs in the next release. If medical costs spike above last year's 94.8% fourth-quarter ratio, it would signal that underlying care usage is eating into 2027 insurance pricing.
Client Price Concessions Squeeze Pharmacy Benefit Margins
Health Services houses Caremark, the pharmacy benefit manager (PBM) that negotiates drug prices for 87 million plan members, alongside Oak Street Health clinics. Segment revenue jumped 9.5% from a year ago to $54.0 billion on expensive specialty drugs and brand inflation. Yet segment operating profit, excluding one-offs, grew only 2.7% to $2.11 billion, as CVS Health cited "continued pharmacy client price improvements"—meaning lower prices charged to clients.
Those price concessions pushed cost of products sold up by 0.3 percentage points of segment revenue, trimming the division's operating margin excluding one-offs from 4.2% to 3.9%. Pharmacy claims processed rose just 1.3% to 481.7 million, showing that volume growth is too slow to easily offset the margin squeeze before 2027 client exits arrive.
What to watch: Health Services operating profit margin in the fourth quarter. A further drop below 3.5% would show client pricing pressure is worsening ahead of next year's contract renewals.
Omnicare Bankruptcy Settlement Adds Another Legal Charge
CVS Health treats legal settlements as one-off adjustments, but legal bills hit the income statement almost every year. After booking $1.54 billion of legacy and opioid litigation charges in 2025, the company recorded a new $193 million charge ($0.15 per share) this quarter for "agreements to resolve certain litigation and Chapter 11 bankruptcy matters involving Omnicare," its former long-term care pharmacy unit that entered bankruptcy in September 2025.
Following bankruptcy court approval in August 2026, CVS Health expects Omnicare's assets to be sold in the fourth quarter, triggering this contingent guarantee liability. Because these legal costs require real cash payouts over time, repeated exclusions make profit excluding one-offs look cleaner than the cash reality.
What to watch: final cash payments required upon the fourth-quarter sale of Omnicare's assets. Any increase above the $193 million accrual would further drain cash meant for debt reduction.
Risks this quarter didn't answer
Three standing risks and segment outlook updates did not appear in the third-quarter earnings release because management typically reserves detailed forward commentary and legal disclosures for the conference call and quarterly filing.
- Caremark 2027 earnings pressure: management promised to size 2027 headwinds from 340B drug-discount changes and client losses on the third-quarter call, which is not in the release.
- Segment full-year outlooks: the release gave only enterprise-wide targets, leaving updates to segment profit and medical benefit ratio targets for the call and filing.
- PBM regulation and FTC settlement: any progress on finalizing the Federal Trade Commission settlement or challenging state pharmacy ownership bans will appear in the quarterly filing's legal note.
- Medicare coding audits: updates on federal Risk Adjustment Data Validation (RADV) audits and Justice Department inquiries live in the quarterly filing.
👓 Other Themes
Weight-Loss And App Services Expand Consumer Reach
CVS Health is pushing direct-to-consumer digital and clinical offerings to connect its clinics and drugstores. It now pairs a MinuteClinic digital weight-loss visit with same-day pickup of GLP-1 weight-loss drugs at 9,000 pharmacies "in one connected experience, with no membership or recurring monthly fee." Separately, its Health100 mobile app earned DirectTrust consumer privacy accreditation to help patients compare care costs and manage chronic conditions, though neither announcement included revenue figures.
💲 Other KPIs
Total debt—short-term plus long-term borrowings—fell 6.0% ($3.89 billion) from $64.57 billion at the end of 2025, by our math. CVS Health repaid $4.06 billion of long-term debt over the first nine months while issuing no new long-term debt and buying back zero shares, keeping cash focused on repairing the balance sheet.
Total people covered by Aetna health plans edged up by 97,000 from the second quarter, stabilizing after a 583,000 drop from a year ago caused by exiting the individual insurance exchanges. Days claims payable—how many days of medical bills sit in reserves—rose 0.2 days from last quarter to 41.9 days, indicating steady reserve coverage.
Weighted average diluted shares rose 1.7% from 1,269 million a year ago (and 1.5% against last year's 1,272 million adjusted share count). Because the healthcare group paused share buybacks to pay down debt, employee stock compensation continues to slowly increase the share count and dilute per-share earnings.
🔮 Guidance
Raised. The healthcare group lifted its full-year sales floor by $6.0 billion, pointing to at least 4.5% growth for the year, by our math. That leaves at least $105.1 billion of revenue for the fourth quarter, down 0.6% from a year ago after 5.4% growth in the third quarter, reflecting the Omnicare exit and drug price cuts.
Raised. Management switched from a range to a floor that sits $0.04 above the prior middle of $6.94, even after absorbing a new $0.15 per share Omnicare legal charge. With $6.29 earned in the first nine months, the floor leaves at least $0.69 for the fourth quarter by our math, compared with $2.30 a year ago when a one-time tax benefit boosted profit.
Raised. The new floor sits $0.20 above the middle of the prior range and represents at least 21.5% growth for the year. It is the third raise this year: +$0.30 in the first quarter, +$0.60 in the second, and +$0.20 now. By our math, the floor leaves at least $0.96 for the fourth quarter, down 12% from $1.09 a year ago.
Raised. The company lifted its operating cash flow floor by $4.0 billion, its third increase this year (+$0.5B, +$2.0B, +$4.0B). Because the business already generated $15.32 billion in the first nine months, the new floor requires just $182 million of operating cash flow in the fourth quarter by our math, building in a large buffer for late-year payment timing.
❓ Key Questions
How big are the 2027 pharmacy benefit headwinds?
Last quarter, management promised to share 2027 headwinds and tailwinds on the third-quarter call. Investors need the dollar impact of manufacturer restrictions in the 340B drug-discount program and expected Caremark client losses.
What are the updated full-year segment profit targets?
Nine-month insurance operating profit of $6.38 billion already beat the prior $5.03–5.37 billion full-year range. Management did not print updated segment profit or medical benefit ratio ranges in the release.
How much will working capital reverse in the fourth quarter?
Nine-month operating cash flow reached $15.32 billion, boosted by $3.56 billion from working capital timing, while the new full-year floor is at least $15.5 billion. That implies almost no cash flow in the fourth quarter unless the target is conservative.
Did current-year medical cost trends worsen in the third quarter?
Favorable development of prior years' medical reserves slowed to about $100 million in the third quarter from $1.2 billion in the first half, while the medical benefit ratio rose to 91.3%. Clarifying underlying hospital utilization will show if 2027 plan pricing is sufficient.